Verrica Pharmaceuticals Inc (VRCA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $54.97M
Last updated: Nov 17, 2026 at 4:32 PM ET
Verrica Pharmaceuticals Inc (VRCA) Statistics
Verrica Pharmaceuticals (VRCA) has a market cap of $54.97M and an enterprise value of $52.99M. Its share count is up 124.50% from a year earlier. It kept -189.23% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 3.61% below the market cap, as cash exceeds debt.
| Market Cap | $54.97M |
|---|---|
| Enterprise Value | $52.99M |
| Latest price (Nov 17, 2026) | $3.14 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 2.9x. Its year-end P/S ranged from 0.5x to 280.6x from 2021 to 2025.
| P/S Ratio | 2.9x |
|---|---|
| Forward P/S | 2.2x |
Price Statistics
The stock is down 20.10% over 52 weeks and trades 21.11% below its 50-day average.
| Beta (1Y) | 2.23 |
|---|---|
| 52-Week Change | -20.10% |
| 1-Month Change | -8.72% |
| 3-Month Change | -37.07% |
| 6-Month Change | -43.83% |
| 5-Year Change | -97.34% |
| Total Return (1Y) | -20.10% |
| Total Return (3Y CAGR) | -55.27% |
| Total Return (5Y CAGR) | -51.15% |
| Return vs SPY (1Y) | -29.57% |
| Max Drawdown (1Y) | -66.04% |
| Max Drawdown (3Y) | -96.77% |
| Sharpe Ratio (1Y) | -0.22 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $3.98 |
| 200-Day Average | $5.36 |
| 52-Week Range | $3.08 to $9.82 |
| RSI (14 Days) | 39.8 |
| Average Volume (20 Days) | 57.70K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.66x current liabilities.
| Current Ratio | 1.66x |
|---|---|
| Quick Ratio | 1.53x |
| Interest Coverage | -11.70x |
Returns and Efficiency
Return on invested capital is -496.25% over the last 12 months, against a 5-year average of -90.57%.
| Return on Assets (ROA) | -108.67% |
|---|---|
| Return on Invested Capital (ROIC) | -496.25% |
| Return on Capital Employed (ROCE) | -225.43% |
| ROA (5Y Average) | -72.01% |
| ROIC (5Y Average) | -90.57% |
| Asset Turnover | 0.57x |
| Inventory Turnover | 0.81x |
| Receivables Turnover | 2.06x |
| Cash Conversion Cycle | 391 days |
Scores
VRCA has an Altman Z-Score of -14.11, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -14.11 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $22.89M over the last 12 months is down 25.75% from the 12 months before.
| Revenue | $22.89M |
|---|---|
| Revenue Growth (YoY) | -25.75% |
| Gross Profit | $20.65M |
| Operating Income | -$42.17M |
| Pretax Income | -$43.32M |
| Net Income | -$43.32M |
| EBITDA | -$39.62M |
| EBIT | -$40.42M |
| Reported EPS (TTM) | -$2.08 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $14.39M |
|---|---|
| Total Debt | $12.41M |
| Net Cash | $1.99M |
| Net Cash Per Share | $0.09 |
| Working Capital | $14.47M |
| Shareholder Equity | -$5.97M |
| Total Assets | $39.86M |
| Total Liabilities | $45.84M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$32.07M |
|---|---|
| FCF Per Share | -$1.87 |
| Depreciation and Amortization | $798.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -184.23%.
| Gross Margin | 90.23% |
|---|---|
| Operating Margin | -184.23% |
| Pretax Margin | -189.23% |
| Net Margin | -189.23% |
| EBITDA Margin | -173.10% |
| EBIT Margin | -176.58% |
| Gross Margin (5Y Average) | 92.74% |
Growth
Revenue grew 57.93% a year over 3 years.
| Revenue Growth (3Y CAGR) | +57.93% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -26.22% |
| Tangible Book Per Share Growth (2Y CAGR) | -26.22% |
Stock Splits
The last split was a 1-for-10 reverse split on Jul 25, 2025.
| Last Split Date | Jul 25, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 4 similar companies, VRCA has the 3rd highest P/S and the lowest ROIC.
P/S RatioPeer median 9.7x
ROICPeer median -109.22%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -14.70%
| P/S Ratio | 2.9x vs 9.7x median |
|---|---|
| ROIC | -496.25% vs -109.22% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -25.75% vs -14.70% median |
Analyst Forecast
Consensus estimates put revenue growth at 4.37% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +4.37% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About VRCA
What is VRCA's market cap?
Verrica Pharmaceuticals has a market cap of $54.97M. Its enterprise value, which adds debt and subtracts cash, is $52.99M.
How many shares of VRCA are outstanding?
Verrica Pharmaceuticals has 21.31M shares outstanding. The count is up 124.50% from a year earlier.
Does VRCA pay a dividend?
No. Verrica Pharmaceuticals does not pay a dividend.
How much debt does VRCA have?
Verrica Pharmaceuticals has $12.41M of total debt and $14.39M of cash and equivalents, a net cash position of $1.99M.
VRCA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors